27 Mar Subsidised Folotyn now available to all Australian’s in need
Mundipharma has welcomed the announcement that the anti-cancer medicine Folotyn® injection (pralatrexate) will be subsidised for patients following its listing on the Pharmaceutical Benefit Scheme (PBS). Folotyn® is used to treat patients aged 18 years or older with peripheral T-cell lymphoma (PTCL) after previous treatments have...